3Lindholm L, Holmgren J, Svennerholm L, et al. Monoclonal antibod ies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides [J]. Int Arch Allergy Appl Immunol, 1983, 71(2): 178-81.
4Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA199 for the diagnosis of pancreatic cancer[J]. Br J Cancer, 1994, 70(3): 481-6.
5Palsson B, Masson P, Andren-Sandberg A. The influence ofcholesta sis on CA50 and CA242 in pancreatic cancer and benign biliopancreatic diseases [ J ]. Scand J Gastroenterol, 1993, 28( 11): 981-7.
6Ichihara T, Nomoto S. Clinical usefulness of the immunostaining of the tumor markers in pancreatic cancer [ J ]. Hepatogastroenterology, 2001, 48(40): 939-43.
7Chu JS, Chang KJ. Mucin expression in mucinous carcinoma and other invasive carcinomas of the breast[J]. Cancer Lett, 1999, 142 (1): 121-7.
8Huglund C, Lundin J, Roberts PJ, et cd. CA242, a new tumor marker for pancreatic cancer a comparison with CA199, CA50 and CEA[J]. Br J Cancer, 1994, 70(4): 487-92.
9Watanabe M, Chigusa M, Takahashi H, et al. High level of CA19-9,CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo[J]. In Vitro Cell Dev Biol Anim, 2000, 36(2): 104-9.
10Kuusels, Haglund C, Roberts PJ. Comparison of a new tumour mark er CA242 with CA19-9, CA50 and carcinoembryonic antigen (CEA) in digestive tract diseases [ J ]. Br J Cancer, 1991, 63(4): 636-40.
